Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01542541 · ClinicalTrials.gov registry record · NA
A Clinical Study to Limit Physiologic Intestinal FDG Uptake Uptake on PET-CT Scans
A NA study, sponsored by Beth Israel Deaconess Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 68
- Enrollment target
NCT01542541 is a NA study that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 68 participants.
The verdict
NCT01542541, a NA study, has completed, sponsored by Beth Israel Deaconess Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 68 participants
- Enrollment target
Study Summary
Patients who undergo PET-CT scans to look for cancer are given an intravenous contrast (FDG) that is taken-up by active cells such as cancer cells. This contrast can then be seen in the body using the PET-CT scanner. However, cells in the colon also take up the FDG, and can produce "false positive" signals from the colon. Our hypothesis is that much of this signal comes from bacteria that are present in high concentrations in the colon. If this is the case, using an antibiotic to suppress the activity of bacteria may improve the ability of PET-CT to distinguish abnormal cells from normal cells in the colon.
Interventions
- DRUG Rifaximin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2011-07 |
| Est. Completion | 2012-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01542541
The ClinicalTrials.gov registry entry for NCT01542541 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rifaximin is the first listed.
NCT01542541 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01542541 about?
NCT01542541 is a clinical study titled "A Clinical Study to Limit Physiologic Intestinal FDG Uptake Uptake on PET-CT Scans". Patients who undergo PET-CT scans to look for cancer are given an intravenous contrast (FDG) that is taken-up by active cells such as cancer cells. This contrast can then be seen in the body using the PET-CT scanner. However, cells in the colon also take up the FDG, and can produce "false positive" ...
What is the current status of trial NCT01542541?
This trial is currently completed. It is a NA study. The enrollment target is 68 participants. The study started on 2011-07. Estimated completion is 2012-10.
What interventions are being tested in trial NCT01542541?
The interventions under investigation include: Rifaximin (DRUG).
Who is sponsoring clinical trial NCT01542541?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.